Dhanasekaran Renumathy, Limaye Alpna, Cabrera Roniel
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Florida, Gainesville, FL, USA.
Hepat Med. 2012 May 8;4:19-37. doi: 10.2147/HMER.S16316.
Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its incidence is on the rise in the developing world. The epidemiology of this cancer is unique since its risk factors, including hepatitis C and B, have been clearly established. The current trends in the shifting incidence of HCC in different regions of the world can be explained partly by the changing prevalence of hepatitis. Early detection offers the only hope for curative treatment for patients with HCC, hence effective screening strategies for high-risk patients is of utmost importance. Liver transplantation and surgical resection remains the cornerstone of curative treatment. But major advances in locoregional therapies and molecular-targeted therapies for the treatment of advanced HCC have occurred recently. In this review, current trends in the worldwide epidemiology, surveillance, diagnosis, standard treatments, and the emerging therapies for HCC are discussed.
肝细胞癌(HCC)是发展中国家常见的恶性肿瘤,在发展中世界其发病率呈上升趋势。这种癌症的流行病学具有独特性,因为其风险因素,包括丙型肝炎和乙型肝炎,已被明确确定。世界不同地区HCC发病率变化的当前趋势部分可以通过肝炎患病率的变化来解释。早期检测为HCC患者提供了治愈性治疗的唯一希望,因此针对高危患者的有效筛查策略至关重要。肝移植和手术切除仍然是治愈性治疗的基石。但近年来,局部区域治疗和晚期HCC分子靶向治疗取得了重大进展。在这篇综述中,讨论了全球范围内HCC的流行病学、监测、诊断、标准治疗以及新兴治疗方法的当前趋势。